Clinical trials: Coronavirus (SARS-CoV)
Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome
Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome, Type 2 Diabetes
- Trial name
- DMMETCOV19 (NCT04626089)
- Testing
- metformin glycinate
- Where
- Mexico
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Covid-19, Nosocomial Infection
COG-UK Project Hospital-Onset COVID-19 Infections Study
Hospitals are recognised to be a major risk for the spread of infections despite the availability of protective measures. Under normal circumstances, staff may acquire and transmit infections, but the health impact of within…
- Conditions
- Covid-19, Nosocomial Infection, Coronavirus, Coronavirus Infection
- Trial name
- COG-UK HOCI (NCT04405934)
- Testing
- Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures
- Where
- United Kingdom
- Volunteers
- 2,170 people
- Sponsor
- University College, London
Chronic Pain, Chronic Pain Syndrome
Outcomes Mandate National Integration With Cannabis as Medicine
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma
- Trial name
- OMNI-Can (NCT03944447)
- Testing
- Cannabis, Medical, RYAH-Medtech Inhaler
- Where
- 17 sites in United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- OMNI Medical Services, LLC
Covid-19, Corona Virus Infection
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
Introduction There are currently no treatments with demonstrated efficacy for COVID-19 infection. Epidemiological evidence points to the existence of intrinsic protection factors which make young persons and women more resistant…
- Conditions
- Covid-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- OsCOVID19 (NCT04386447)
- Testing
- Oxytocin, Standard of Care
- Where
- 3 sites in France, Italy
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Coronavirus (SARS-CoV)
SARS Coronavirus Vaccine (SARS-CoV)
Severe acute respiratory syndrome (SARS) is a viral illness that affects the respiratory (breathing) system. The purpose of this study is to evaluate the safety and protective (immune) responses to different doses of a SARS…
- Trial name
- NCT00533741
- Testing
- Aluminum hydroxide, SARS-CoV
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS CoV 2 Infection
Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies
Natural infection, vaccines and treatments (like monoclonal antibodies) lead to the appearance of a neutralizing power in the serum (due to induced or injected antibodies).
- Trial name
- PNAS (NCT05315583)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Covid19, SARS-CoV Infection
The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection
The ongoing pandemic of SARS CoV-2 virus is calling for effective preventive and theraputic interventions. Vitamin D has been shown to play immunemodulatory functions in human.
- Trial name
- NCT04733625
- Testing
- Cholecalciferol
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Kasr El Aini Hospital
Coronavirus
COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study
A phase I, experimental dose finding, open label, clinical infection, safety and viral detection optimisation in previously SARS-CoV-2 infected (unvaccinated or vaccinated) or uninfected vaccinated volunteers.
- Trial name
- NCT04864548
- Testing
- SARS-CoV-2 virus
- Where
- 3 sites in United Kingdom
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of Oxford
SARS-CoV Infection, Anxiety
COVID-19-Related Health and Practices Among Dental Hygienists
As dental practices reopen their practices during a global pandemic, the risk of 2019 novel coronavirus (COVID-19) infection that dental hygienists face in providing dental care remains unknown.
- Conditions
- SARS-CoV Infection, Anxiety, Depression, Occupational Problems
- Trial name
- NCT04542915
- Testing
- No intervention
- Where
- United States
- Volunteers
- 6,976 people, healthy volunteers welcome
- Sponsor
- American Dental Association
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Corona Virus Infection, Middle East Respiratory Syndrome (MERS)
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients.
- Conditions
- Corona Virus Infection, Middle East Respiratory Syndrome (MERS), Acute Respiratory Distress Syndrome, Coronavirus Infection
- Trial name
- COVID-19_LF (NCT04412395)
- Testing
- Lactoferrin (Apolactoferrin)
- Where
- 4 sites in Egypt
- Volunteers
- 516 people
- Sponsor
- National Research Centre, Egypt
SARS-CoV Infection, Covid19
Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept
The main objective of this CorDial-S proof-of-concept study is to evaluate the ability to detect COVID-19 infection in nasopharyngeal swabs with CorDial-S and compare it to the PCR technique currently in use.
- Trial name
- COR-DIAL-S (NCT04780334)
- Testing
- COVID-19 RT-PCR, Biosensor
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Lille
COVID-19, SARS-CoV 2
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
- Trial name
- NCT04372017
- Testing
- Hydroxychloroquine, Vitamin D
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sanford Health
SARS-CoV Infection, COVID-19
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to…
- Conditions
- SARS-CoV Infection, COVID-19, Anosmia, Dysgeusia
- Trial name
- NCT04384042
- Testing
- Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
- Where
- 14 sites in Malaysia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Sultanah Bahiyah
SARS-CoV Infection, Covid19
Can the Electronic Nose Smell COVID-19 Antibodies?
Corona Virus Disease (COVID-19), spread worldwide and has become an emergency of major international concern. In March 2020, the WHO declared the COVID-19 outbreak a global pandemic.
- Trial name
- NCT04475575
- Testing
- Aeonose
- Where
- Netherlands
- Volunteers
- 222 people
- Sponsor
- Maastricht University Medical Center
SARS-CoV Infection, Seroprevalence
COVID-19 Sero-prevalence Health Care Workers Kinshasa
This is a cohort study, in which the investigators will follow-up 650 health care workers (HCW) and a selection of their households (of COVID positive and COVID negative HCW) at baseline and in three follow-up surveys, with 4 to…
- Trial name
- PRESTACOV (NCT04699058)
- Testing
- COVID-antibody test
- Where
- Democratic Republic of the Congo
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
SARS-CoV 2
Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.
According to different projections, the COVID-19 outbreak currently happening in France and worldwide could result in millions of deaths in the absence of efficient therapies.
- Trial name
- AcNT-COVID19 (NCT04596098)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Grenoble
SARS CoV 2 Infection
Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.
To evaluate the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine plus a homologous boostwith Ad26.COV2.S COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonkeparticipants; vaccinated; and…
- Trial name
- Sisonke Boost (NCT05148845)
- Testing
- Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S
- Where
- 31 sites in South Africa
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Wits Health Consortium (Pty) Ltd
COVID-19, Corona Virus Infection
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- C-PIC (NCT04448145)
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Columbia University